Amylyx Pharmaceuticals, Inc. (AMLX) — Dilution Risk Analysis

Current Snapshot

Amylyx Pharmaceuticals, Inc. (AMLX) has a DilutionWatch score of 27/10 and is classified as MEDIUM risk. The score date in the source data is 2026-10-03T03:45:52.527348.

This page is assembled from sourced share-structure, market-data, SEC-filing, and DilutionWatch fields. Missing values are left blank rather than estimated.

Share Structure

Shares Outstanding
111,423,048 Source
Public Float
83,528,721 Source
Float as % of Outstanding
75.0%

Dilution Risk Score

Score: 27/10 Source (as of 2026-10-03T03:45:52.527348)

Recent SEC Filings

Recent filing forms in the source payload: 4 9, 8-K 1.

FormFiledAccession
4 2026-09-14 0001193125-26-390507
4 2026-09-14 0001193125-26-390506
4 2026-09-14 0001193125-26-390508
4 2026-09-14 0001193125-26-390509
4 2026-09-14 0001193125-26-390510
4 2026-09-02 0001193125-26-380152
8-K 2026-08-20 0001193125-26-359418
4 2026-08-20 0001193125-26-359675
4 2026-08-20 0001193125-26-359676
4 2026-08-20 0001193125-26-359677

Dilution Risk Drivers

DriverStored ValueSource
Cash runway 41 months Source
Three-year share count growth 65.03% Source

DilutionWatch Analysis

Risk Level
MEDIUM (Score: 27/10) Source
Cash Runway
41 months Source
Share Count Growth (3-Year)
65.03% Source

What This Page Does Not Estimate

DilutionWatch does not infer missing cash runway, authorized share count, ATM capacity, shelf capacity, or share-growth values on this page. A blank field means the current source payload did not provide a usable value with provenance.

Scores and classifications are shown only when supplied by the DilutionWatch data layer. SEC filing rows link to their source accession when a filing URL is available.